FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine. Tasimelteon 20 mg is administered orally before bedtime.
EFFECT: group of inventions provides improved sleep, performance after sleep, without inducing effects after sleep, which impair the ability of a subject to control equipment or a vehicle.
9 cl, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| USE OF TASIMELTEON IN TREATMENT OF SLEEP DISORDERS | 2020 |
|
RU2833599C2 |
| WAY TO IMPROVE SLEEP | 2020 |
|
RU2804441C2 |
| TREATMENT OF CIRCADIAN RHYTHM DISORDERS | 2013 |
|
RU2748386C2 |
| APPLICATION OF MEDICATION FOR TREATING SLEEP DISTURBANCES | 2004 |
|
RU2354374C2 |
| USE OF AN INVERSE AGONIST H3R FOR TREATING SLEEP DISORDER IN SHIFT WORK | 2018 |
|
RU2768894C2 |
| MELATONIN AGONIST THERAPY | 2007 |
|
RU2488392C2 |
| METHODS AND COMPOSITIONS FOR IMPROVING SLEEP IN ANIMALS | 2011 |
|
RU2594876C2 |
| USING MIRTAZAPINE FOR TREATMENT OF SLEEP DISORDER | 2001 |
|
RU2270680C2 |
| METHOD FOR SLEEP NORMALIZATION | 2002 |
|
RU2218933C2 |
| METHODS FOR TREATMENT OF DISORDERS OF CIRCADIAN SLEEP RHYTHM | 2017 |
|
RU2763493C2 |
